Novella Clinical Appoints Vice President, Clinical Operations in Europe

RESEARCH TRIANGLE PARK, N.C., Aug 26, 2010 (BUSINESS WIRE) -- Novella Clinical Inc. announced today that it has appointed Jane Bentley PhD, as Vice President, Clinical Operations. Dr. Bentley is responsible for leading European clinical operations for Novella, as well as promoting the company's values, vision and growth.

Jane has a wealth of clinical research experience having worked with large pharma, including GlaxoSmithKline and Roche, as well as with CROs and the service sector. She joins Novella after a 15 year engagement with i3, where, most recently, she held the position of Senior Therapeutic Director for Oncology (Europe, Middle East and Africa). Her strong background in oncology aligns well with Novella's corporate growth strategies, which include recent acquisitions of Prologue Research and OSI's Boulder office.

"Jane has a proven track record of leading and motivating teams, and providing an unrivalled level of service and strategic development advice to Sponsor companies. Jane has successfully led teams across Europe and the Middle East Region, as well as global programmes in oncology and provides a level of expertise and knowledge that really facilitates programme development. We are delighted to have Jane join the Novella team," commented Nigel Trim, Managing Director, European Operations.

"I am delighted to be joining the team and to utilize my background in operations management and business development in an exciting new direction and to support the future growth of the Global business for Novella," added Dr. Bentley.

About Novella Clinical

For over a decade, Novella Clinical has been an active partner in supporting the biopharma and medical device industries with early phase through post-marketing development programs. Although our clinical experience is all-inclusive, our eClinical roots enable us to offer services that are specific to our clients' needs, often eliminating the demand to contract with multiple partners. From protocol development through final clinical study report -- we integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. Our focus on quality customer service is reflected in our certification by Underwriters Laboratories on meeting global quality standards (ISO 9001:2008). For more information, visit www.novellaclinical.com.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.